NKTX Nkarta
- 7.940
- +0.410+5.44%
Nkarta News
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
Small-Cap Firm Century Therapeutics' Expands Into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indicat
Needham: Reiterates the Nkarta (NKTX.US) rating and adjusted from buy to buy rating, target price is $15.00.
Needham: Reiterates the Nkarta (NKTX.US) rating and adjusted from buy to buy rating, target price is $15.00.
Needham Reiterates Buy on Nkarta, Maintains $15 Price Target
Needham analyst Gil Blum reiterates Nkarta with a Buy and maintains $15 price target.
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)
Nkarta to Participate in Upcoming Investor Conferences
PDF Version SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, to
Nkarta(NKTX.US) Director Buys US$20 Million in Common Stock
$Nkarta(NKTX.US)$ Director George Simeon purchased 2 million shares of Common Stock on Mar 27, 2024 at an average price of $10 for a total value of $20 million.Source: Announcement What is statement o
Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-hearted
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
Nkarta Price Target Raised to $16.00/Share From $15.00 by Canaccord Genuity
Nkarta Price Target Raised to $16.00/Share From $15.00 by Canaccord Genuity
Nkarta Is Maintained at Buy by Canaccord Genuity
Nkarta Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Nkarta, Raises Price Target to $16
Canaccord Genuity analyst Bill Maughan maintains Nkarta with a Buy and raises the price target from $15 to $16.
12 Health Care Stocks Moving In Monday's Intraday Session
GainersLandos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came ou
Unlocking The Momentum: Nkarta (NKTX) Stock On The Rise
The current surge in Nkarta, Inc. (NASDAQ: NKTX) shares on the US stock market indicates a remarkable increase of 22.42%, reaching $10.92 per share at the last check. This notable upswing in NKTX stock value is attributed to a strategic equity maneuver. In an underwritten offering of 21,010,000 shares of its common stock, Nkarta (NKTX) ...
Nkarta Is Maintained at Buy by HC Wainwright & Co.
Nkarta Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $22
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta with a Buy and raises the price target from $20 to $22.
Nkarta Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 101.93% HC Wainwright & Co. $20 → $22 Maintains Buy 03/22/2024 129.46% Mizuho $31 → $25 Maintai
Crude Oil Moves Higher; US New Home Sales Fall In February
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S
Nkarta, Nuvation Bio, Canopy Growth Among Healthcare Movers
Nkarta Shares Rise 23% After Public Offering Prices
By Chris Wack Nkarta shares were up 23% at $10.99 after the company priced an underwritten offering of 21 million shares at $10 a share, and pre-funded warrants to buy 3 million shares of common stoc
Analysis
Price Target
No Data
